Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Farxiga is expected to have such a strong influence on the market due to the impressive results
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
